Market Place
Sourcing Support
Barinthus Bio Completes Enrollment in Chronic Hepatitis B Trial
01 Oct 2024 //
GLOBENEWSWIRE
Barinthus Bio Starts VTP-1000 Phase 1 Trial for Celiac Disease
24 Sep 2024 //
GLOBENEWSWIRE
Barinthus Bio Reports Q2 2024 Update On Developments And Results
08 Aug 2024 //
GLOBENEWSWIRE
Barinthus lays off 25%, sidelines prostate cancer program
13 Jun 2024 //
FIERCE BIOTECH
Barinthus Bio Announces Pipeline Prioritization After VTP-300 Data
12 Jun 2024 //
GLOBENEWSWIRE
Barinthus Bio`s VTP-300 Trials Show Undetectable HBsAg And HBsAg Lowering
06 Jun 2024 //
GLOBENEWSWIRE
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
22 May 2024 //
GLOBENEWSWIRE
Barinthus Bio Reports Q1 2024 Results, Corporate Developments Update
13 May 2024 //
GLOBENEWSWIRE
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as CMO
01 May 2024 //
GLOBENEWSWIRE
Barinthus Bio`s HPV immunotherapy underwhelms in early study
20 Apr 2024 //
PRESS RELEASE
Barinthus Bio Reports Topline Phase 1b/2 VTP-200 HPV Infection Data
18 Apr 2024 //
GLOBENEWSWIRE
Barinthus Bio Reports Full Year 2023 Financial Results and Update on
20 Mar 2024 //
GLOBENEWSWIRE
Barinthus Bio Provides a Financial Update
05 Jan 2024 //
GLOBENEWSWIRE
New partnership aims to advance vaccine against MERS coronavirus
21 Dec 2023 //
GLOBENEWSWIRE
Barinthus` gets $35M booster from CEPI to develop MERS shot
21 Dec 2023 //
FIERCE BIOTECH
Vaccitech reemerges as Barinthus with hep B data
10 Nov 2023 //
FIERCE BIOTECH
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution
06 Nov 2023 //
GLOBENEWSWIRE
Vaccitech Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Vaccitech Doses First Patient in PCA001, Phase 1/2 Clinical Trial of VTP-850
12 Jun 2023 //
GLOBENEWSWIRE
Vaccitech Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Vaccitech Announces Data for HBV002 Study in People with Chronic Hepatitis B
28 Mar 2023 //
GLOBENEWSWIRE
Vaccitech Reports Full-Year 2022 Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Vaccitech Appoints Nadège Pelletier, Ph.D., as Chief Scientific Officer
30 Jan 2023 //
GLOBENEWSWIRE
Vaccitech to Host KOL Webinar on the SNAPvax Platform
21 Nov 2022 //
GLOBENEWSWIRE
Vaccitech Reports 3Q 2022 Financial Results and Recent Corporate Developments
10 Nov 2022 //
GLOBENEWSWIRE
Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial
07 Nov 2022 //
GLOBENEWSWIRE
Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD
02 Nov 2022 //
GLOBENEWSWIRE
Vaccitech to Present at Upcoming October Investor & Scientific Conferences
03 Oct 2022 //
GLOBENEWSWIRE
Vaccitech Promotes Gemma Brown as CFO
20 Sep 2022 //
FIRSTWORLDPHARMA
Vaccitech to Present at Upcoming September Investors Conferences
07 Sep 2022 //
GLOBENEWSWIRE
Oxford Science Enterprises clinches £250M for new startups
18 Jul 2022 //
FIERCEBIOTECH
Vaccitech to Present at the William Blair Biotech Focus Conference 2022
07 Jul 2022 //
GLOBENEWSWIRE
VTP-300 induced sustained reductions of surface antigen in chronic hepatitis B
22 Jun 2022 //
GLOBENEWSWIRE
Arbutus and Vaccitech Dose First Patient in PIIa Trial Combining Therapies
06 Jun 2022 //
GLOBENEWSWIRE
Vaccitech to Present at the Jefferies Healthcare Conference
06 Jun 2022 //
GLOBENEWSWIRE
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
20 May 2022 //
GLOBENEWSWIRE
Vaccitech Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Vaccitech Announces Notification of Milestone and Royalty Revenue
06 Apr 2022 //
GLOBENEWSWIRE
Vaccitech Reports Full-Year 2021 Financial Results
25 Mar 2022 //
GLOBENEWSWIRE
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
07 Mar 2022 //
GLOBENEWSWIRE
Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer
18 Jan 2022 //
GLOBENEWSWIRE
Vaccitech to Host Virtual KOL Event on VTP-300 for CHB Infection
13 Jan 2022 //
GLOBENEWSWIRE
Vaccitech acquires Avidea Technologies to expand product pipeline
13 Dec 2021 //
GLOBENEWSWIRE
Vaccitech reports promising interim efficacy in Phase 1b/2a clinical study
07 Dec 2021 //
GLOBENEWSWIRE
Vaccitech to Participate at The 33rd Virtual Piper Sandler Healthcare Conference
24 Nov 2021 //
GLOBENEWSWIRE
Vaccitech Reports Q3 2021 Financial Results and Recent Corporate Developments
12 Nov 2021 //
GLOBENEWSWIRE
Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results
03 Nov 2021 //
GLOBENEWSWIRE
Vaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021
18 Oct 2021 //
GLOBENEWSWIRE
Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic
13 Oct 2021 //
GLOBENEWSWIRE
Vaccitech moves to new headquarters; EnteroBiotix raises $21.5M in Series A
07 Sep 2021 //
ENDPTS
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
08 Jul 2021 //
GLOBENEWSWIRE
Vaccitech Completes $168 Million Series B Financing to Advance Three Programs
17 Mar 2021 //
GLOBENEWSWIRE
AstraZeneca receives approval to resume COVID-19 vaccine AZD1222 clinical trials
13 Sep 2020 //
PHARMABIZ
Biotech behind AstraZeneca`s COVID-19 vaccine advances next-gen prospect
27 Aug 2020 //
FIERCE PHARMA
Biotech behind AstraZeneca`s COVID-19 vaccine advances next-gen prospect
27 Aug 2020 //
FIERCE BIOTECH
Vaccitech receives government grant for COVID-19 vaccine research
26 Aug 2020 //
VACCITECH
In conversation with Vaccitech CEO Enright
23 Jul 2020 //
FIERCE BIOTECH
Vaccitech and Oxford University Announce Promising Phase 2a Data
23 Mar 2020 //
B3CNEWSWIRE
